These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35290662)

  • 1. Association of pre-existing drug allergies with cutaneous immune-related adverse events among patients on immune checkpoint inhibitor therapy.
    Jacoby TV; Otto TS; Asdourian MS; Shah N; Farcasanu M; Chang MS; Thompson LL; Reynolds KL; Chen ST
    Br J Dermatol; 2022 Sep; 187(3):424-426. PubMed ID: 35290662
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor-monoclonal antibodies and desensitization.
    Labella M; Castells M
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):623-629. PubMed ID: 33781937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models.
    Park BC; Stone CA; Dewan AK; Johnson DB
    Immunol Allergy Clin North Am; 2022 May; 42(2):285-305. PubMed ID: 35469619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy.
    Zhou N; Velez MA; Owen D; Lisberg AE
    J Natl Compr Canc Netw; 2020 Sep; 18(9):1287-1290. PubMed ID: 32886906
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockade.
    Asdourian MS; Shah N; Jacoby TV; Semenov YR; Otto T; Thompson LL; Dee EC; Reynolds KL; Chen ST
    J Am Acad Dermatol; 2023 Feb; 88(2):485-487. PubMed ID: 35738514
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy.
    Asdourian MS; Shah N; Jacoby TV; Thompson LL; Otto T; Semenov YR; Reynolds KL; Chen ST
    J Am Acad Dermatol; 2023 Jan; 88(1):246-249. PubMed ID: 35577231
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma.
    Asdourian MS; Otto TS; Jacoby TV; Shah N; Thompson LL; Blum SM; Reynolds KL; Semenov YR; Lawrence DP; Sullivan RJ; Boland GM; Villani AC; Chen ST
    J Am Acad Dermatol; 2022 Nov; 87(5):1147-1149. PubMed ID: 35192899
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.
    Li N; Wang G; Hou X; Tai R; Huang S; He Z; Lei L; Xu S; Yang S
    Int Immunopharmacol; 2022 Jul; 108():108803. PubMed ID: 35569432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors.
    Hirotsu KE; Scott MKD; Marquez C; Tran AT; Rieger KE; Novoa RA; Robinson WH; Kwong BY; Zaba LC
    J Am Acad Dermatol; 2022 Sep; 87(3):651-653. PubMed ID: 34875301
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer immunotherapy-related adverse events: causes and challenges.
    Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
    Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues.
    Ferranti M; Cicogna GT; Messina F; Alaibac M
    Immunotherapy; 2021 Jul; 13(10):795-798. PubMed ID: 33955235
    [No Abstract]   [Full Text] [Related]  

  • 12. Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anticancer therapies: A multicenter retrospective study.
    Asdourian MS; Jacoby TV; Shah N; Thompson LL; Otto T; Semenov YR; LeBoeuf NR; Reynolds KL; Dewan AK; Chen ST
    J Am Acad Dermatol; 2023 Feb; 88(2):474-476. PubMed ID: 35724890
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors.
    Pirozzi F; Poto R; Aran L; Cuomo A; Galdiero MR; Spadaro G; Abete P; Bonaduce D; Marone G; Tocchetti CG; Varricchi G; Mercurio V
    Curr Oncol Rep; 2021 Jan; 23(2):13. PubMed ID: 33415405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 15. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
    Fortes BH; Liou H; Dalvin LA
    Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.
    Khan OF; Monzon J
    Curr Oncol; 2020 Apr; 27(Suppl 2):S43-S50. PubMed ID: 32368173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy.
    Reid PD; Cifu AS; Bass AR
    JAMA; 2021 Feb; 325(5):482-483. PubMed ID: 33528524
    [No Abstract]   [Full Text] [Related]  

  • 19. Rare cutaneous toxicity of immune checkpoint inhibitors: A case of durvalumab-induced dermatomyositis.
    Coustal C; Du Thanh A; Roubille F; Assenat E; Maria ATJ
    Eur J Cancer; 2021 Sep; 155():25-27. PubMed ID: 34332401
    [No Abstract]   [Full Text] [Related]  

  • 20. Skin Reactions to Immune Checkpoint Inhibitors.
    Patel AB; Pacha O
    Adv Exp Med Biol; 2017; 995():175-184. PubMed ID: 28321818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.